MetaCap

Amneal Pharmaceuticals (AMRX) vs Summit Therapeutics (SMMT)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amneal Pharmaceuticals (AMRX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 76.7% versus a loss of 38.5%. Over five years, AMRX leads with a +396.9% price change compared with +92.8% for SMMT. Summit Therapeutics is the larger company by market cap ($7.96 billion vs $7.36 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRX+76.74%SMMT-38.54%
+89%+22%-45%
Nov 21, 20251 yearNov 20, 2026
AMRX+357.14%SMMT+85.98%
+526%+206%-115%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRX versus SMMT key metrics
MetricAMRXSMMT
Share price$21.12$9.95
Market cap$7.36B$7.96B
1-day change-1.26%-5.87%
YTD return+67.62%-43.11%
1-year return+76.74%-38.54%
5-year return+396.94%+92.83%
P/E ratio (TTM)52.80—
Forward P/E17.13—
EPS (TTM)$0.40$-1.06
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.02B—
Revenue growth (YoY)+8.05%—
Net income (latest FY)$72.06M$-1.08B
Gross margin36.88%—
Operating margin13.05%—
Net margin2.39%—
52-week high$22.13$29.23
52-week low$11.71$9.89
Distance from 52-week high-4.54%-65.96%
Analyst consensusstrong_buybuy
Avg. price target upside+15.01%+189.15%
Average volume3.16M6.68M
Shares outstanding348.41M799.76M
Employees8,700265
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMRX has outperformed SMMT by 115.3 percentage points over the past year.

About Amneal Pharmaceuticals

AMRX stock →

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees

About Summit Therapeutics

SMMT stock →

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).

Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees

AMRX vs SMMT FAQ

Which is bigger, Amneal Pharmaceuticals or Summit Therapeutics?

Summit Therapeutics (SMMT) is larger, with a market capitalization of $7.96B compared with $7.36B for Amneal Pharmaceuticals (AMRX).

Which stock has performed better over the past year, AMRX or SMMT?

AMRX returned +76.74% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.

Are Amneal Pharmaceuticals and Summit Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons